Form 8-K - Current report:
SEC Accession No. 0001140361-25-001013
Filing Date
2025-01-14
Accepted
2025-01-14 09:10:10
Documents
16
Period of Report
2025-01-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20040461x2_8k.htm   iXBRL 8-K 32242
2 EXHIBIT 1.1 ny20040461x2_ex1-1.htm EX-1.1 299939
3 EXHIBIT 5.1 ny20040461x2_ex5-1.htm EX-5.1 11491
7 ny20040461x2_ex5-1image01.jpg GRAPHIC 34391
  Complete submission text file 0001140361-25-001013.txt   602695

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ird-20250113.xsd EX-101.SCH 3977
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250113_lab.xml EX-101.LAB 21967
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250113_pre.xml EX-101.PRE 16042
19 EXTRACTED XBRL INSTANCE DOCUMENT ny20040461x2_8k_htm.xml XML 4216
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 25527890
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)